CFDs are a leveraged product and can result in losses that exceed deposits. Trading CFDs may not be suitable for everyone, so please ensure you fully understand the risks and take care to manage your exposure.
Established in 1974
Over 185,000 clients worldwide
15,000 markets worldwide

Preview of ResMed’s Q2 numbers

ResMed is due to release its Q2FY15 on January 23, it will be keenly watched for several reasons:

CFDs are a leveraged product and can result in losses that exceed deposits. Trading CFDs may not be suitable for everyone, so please ensure you fully understand the risks and take care to manage your exposure.
AUD
Source: Bloomberg
  1. FX complexity - AUD/USD will be a benefit, however EUR/USD will headwind
  2. Healthcare multiples - are they justified?
  3. Product momentum and market position

Consensus expectations are for sales to increase 5.6% over the quarter to $407 million.  Operational income is forecasted to be $111 million over the quarter with net profit at $88 million. Solid estimates, yet they would not be considered overly impressive.

Stock specific, current consensus is that mask sales in the US have been muted this quarter. However, the AirCurve generators look to have benefited from its launch mid-way through last year in both the US and European markets and should offset the mask sales issues, as this high-end product attracts a premium.

The sales growth may also be hampered by price cuts introduced in February which are still eating into margins and although no new cuts were introduced over the previous quarter, this cut is still having an impact.

Finally FX, AUD/USD will certainly give ResMed Inc a relief boost to earnings and should boost gross margins, however the EUR will be a major concern to total group revenues and that may negate the tail winds obtained from the AUD. Forecasts for the euro in 2015 are for it to be closer to parity, rather than $1.30 - the price the pair was at this time last year.

 

 

This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.  Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. 

CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.

Find articles by analysts